Testing empagliflozin for Brugada syndrome
Treatments studied
Part of Genetic & congenital, Heart & circulation clinical trials.
This trial tests whether empagliflozin, a diabetes medication, can help people with Brugada syndrome. It aims to see if the drug can reduce the risk of dangerous heart rhythms.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 to 99 years old
- You have been diagnosed with Brugada syndrome and have a specific type of ECG pattern (called type 1) that shows up on its own (not just with fever or drugs)
- Your heart structure and main arteries are normal
- You have not taken any SGLT2 inhibitor (like empagliflozin, dapagliflozin) in the past 12 weeks
- You are not pregnant, nursing, or planning to become pregnant during the study
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at the genes of people with Brugada Syndrome to find new markers that can help doctors diagnose it more accurately. If you have Brugada Syndrome, joining could help improve understanding and care for this condition.
This trial tests whether empagliflozin, a medication for heart failure, can help people who also have end-stage kidney disease and are on dialysis. It aims to see if the drug improves heart function in this group.
This trial tests if empagliflozin, a medication typically used for diabetes, can help people with metabolic syndrome (a cluster of conditions like large waist size, high blood sugar, and high blood pressure). It may improve health and reduce the risk of heart disease.
This study tests whether a diabetes drug (empagliflozin) can improve the heart's ability to relax and fill with blood in people with non-obstructive hypertrophic cardiomyopathy, a type of heart muscle thickening. You may be able to join if you have this condition and are not currently taking an SGLT2 inhibitor.
This trial tests if a diabetes drug called empagliflozin can help the heart's left atrium work better in people who have had a stroke with no known cause. You may join if you are getting a heart monitor device implanted to look for hidden irregular heartbeats.
This trial tests if the drug empagliflozin can improve kidney function in people hospitalized with heart failure who also develop acute kidney injury. It may help protect the kidneys while treating the heart condition.
Hear when a new Brugada Syndrome (BrS) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.